MPNs in focus: disease progression, risk assessment, and emerging treatments

This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington University School of Medicine, St. Louis, MO, discusses mechanisms of disease progression, the DUSP6-RSK1 signaling pathway as a therapeutic target, and the ongoing debate around early versus late intervention in MPNs. Hélène Gleitz, PhD, Erasmus MC, Rotterdam, Netherlands, shares insights into the role of the bone marrow microenvironment and fibrotic niches in disease evolution. Akriti Jain, MD, Cleveland Clinic, Cleveland, OH, discusses the prognostic significance of TP53 mutation acquisition timing, while Yu-Hung Wang, MD, PhD, National Taiwan University Cancer Center, Taipei City, Taiwan, highlights machine learning approaches that model MPNs as a biological continuum. Ciro Rinaldi, MD, PhD, United Lincolnshire Teaching Hospital and University of Lincoln, Lincoln, UK, reviews a Phase II study of momelotinib plus bomedemstat in myelofibrosis, and Marta Sobas, MD, PhD, Wroclaw Medical University, Wroclaw, Poland, discusses ongoing unmet needs and future priorities in MPN care.